Literature DB >> 16153666

Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.

N P Visanji1, S N Mitchell, M J O'Neill, S Duty.   

Abstract

Whilst local intrastriatal infusion of nicotine consistently elicits striatal dopamine release, systemic administration often fails to do so. Since chronic nicotine administration is known to result in desensitisation-induced upregulation of nicotinic acetylcholine receptors (nAChRs), the present study investigated whether chronic pre-treatment could enhance the response to systemic nicotine and, if so, whether increases in specific nAChR subunit mRNA levels in the substantia nigra pars compacta (SNc) may underlie this effect. In vivo microdialysis studies in male Sprague-Dawley rats revealed that following 4 days pre-treatment with nicotine (0.8 mg kg(-1)s.c.), local intrastriatal nicotine infusion (3 mM) elicited significantly higher dopamine efflux compared to vehicle pre-treated controls (peak release: 1273 +/- 199% basal versus 731 +/- 113% basal), whereas systemic nicotine challenge (0.8 mg kg(-1)s.c.) elicited no response. In contrast, following 8 days pre-treatment with nicotine (0.8 mg kg(-1)s.c.), systemic nicotine challenge (0.8 mg kg(-1)s.c.) now produced significantly higher dopamine efflux than that of vehicle pre-treated controls (147 +/- 30% basal versus 91 +/- 5% basal). Eight days pre-treatment with nicotine also significantly elevated the levels of alpha6 (approximately 55%) and beta3 (approximately 43%) nAChR subunit mRNA in the SNc, suggesting that up-regulation of these nAChR subunit genes in the nigrostriatal tract may contribute to the enhanced nicotine-evoked striatal dopamine release.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153666     DOI: 10.1016/j.neuropharm.2005.07.013

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Cellular events in nicotine addiction.

Authors:  Rachel E Penton; Robin A J Lester
Journal:  Semin Cell Dev Biol       Date:  2009-01-20       Impact factor: 7.727

4.  Chronic Menthol Does Not Change Stoichiometry or Functional Plasma Membrane Levels of Mouse α3β4-Containing Nicotinic Acetylcholine Receptors.

Authors:  Selvan Bavan; Charlene H Kim; Brandon J Henderson; Henry A Lester
Journal:  Mol Pharmacol       Date:  2019-01-22       Impact factor: 4.436

5.  bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.

Authors:  Thomas E Wooters; Andrew M Smith; Marharyta Pivavarchyk; Kiran B Siripurapu; J Michael McIntosh; Zhenfa Zhang; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice.

Authors:  Morgane Besson; Vincent David; Mathieu Baudonnat; Pierre Cazala; Jean-Philippe Guilloux; Christelle Reperant; Isabelle Cloez-Tayarani; Jean-Pierre Changeux; Alain M Gardier; Sylvie Granon
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

Review 7.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

8.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

9.  Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway.

Authors:  Cheng Xiao; Raad Nashmi; Sheri McKinney; Haijiang Cai; J Michael McIntosh; Henry A Lester
Journal:  J Neurosci       Date:  2009-10-07       Impact factor: 6.167

10.  Functional alpha7-containing nicotinic acetylcholine receptors localize to cell bodies and proximal dendrites in the rat substantia nigra pars reticulata.

Authors:  Olga V Poisik; Jian-xin Shen; Susan Jones; Jerrel L Yakel
Journal:  J Physiol       Date:  2008-03-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.